



Journal of Coloproctology

www.jcol.org.br



Original article

Anal melanoma: a rare, but catastrophic tumor

Andréa da Costa Veloso, Jaime Coelho Carlos Magno, José Antonio Dias da Cunha e Silva*

Colorectal Division of Hospital Naval Marcílio Dias, Rio de Janeiro, RJ, Brazil

ARTICLE INFO

Article history:

Received 11 September 2013

Accepted 5 December 2013

Keywords:

Anal

Rectal

Melanoma

ABSTRACT

Introduction: Malignant melanoma of the anal canal is a rare and aggressive disease, which early diagnosis is difficult. Its presentation with no specific symptoms leads to a late diagnosis at an advanced stage. The prognosis of anorectal malignant melanoma is poor and frequently related to distant metastasis and absence of response of chemoradiotherapy. Surgery remains the mainstay of therapy; otherwise, the best approach is controversial. Considering no survival benefits for APR, wide local excision should be considered as the treatment of choice.

Methods: This report collects nine cases of anorectal melanoma treated at our division from 1977 to 2006, as well as a review of the literature.

Results: There were eight females and one male, of medium age 69 years (range: 41-85 years). Most frequent presentation was bleeding. Wide Local Excision (WLE) was performed in seven of them. Mean survival was 24 months, and six of them died on account of metastatic disease.

Conclusion: Anorectal melanoma remains challenging. Efforts should be taken to early diagnosis, and wide local excision with negative margins is the preferred treatment. Abdominoperineal resection (APR) is a reasonable option for bulky tumors or when the sphincter is invaded.

© 2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda.

Este é um artigo Open Access sob a licença de [CC BY-NC-ND](http://creativecommons.org/licenses/by-nc-nd/4.0/)

Melanoma anal: tumor raro, mas catastrófico

RESUMO

Introdução: O melanoma maligno do canal anal é uma doença rara e agressiva, em que o diagnóstico precoce se torna difícil. Apresenta-se sem sintomas específicos, levando ao diagnóstico tardio e em fase avançada. O prognóstico é ruim e frequentemente relacionado a metástases a distância, bem como à ausência de resposta à rádio e à quimioterapia. A cirurgia permanece como terapia de escolha, no entanto a melhor abordagem ainda é controversa. Considerando não haver benefício na sobrevida da amputação abdômino-aerineal do aeto (AAPR), a excisão local ampla deve ser considerada o tratamento de escolha.

Métodos: São nove casos de melanoma anorretal tratados no serviço de coloproctologia do Hospital Naval Marcílio Dias (HNMD) de 1977 a 2006.

Palavras-chave:

Anal

Reto

Melanoma

* Corresponding author.

E-mail: joseantoniocunha@yahoo.com.br (J.A.D.d. Cunha e Silva).

2237-9363 © 2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda.

Este é um artigo Open Access sob a licença de [CC BY-NC-ND](http://creativecommons.org/licenses/by-nc-nd/4.0/) <http://dx.doi.org/10.1016/j.jcol.2013.12.005>

Resultados: Foram diagnosticados oito mulheres e um homem, com média de idade de 69 anos (41 - 85). A queixa mais frequente foi o sangramento anal. A excisão local ampla foi realizada em sete pacientes. A sobrevida média foi de 24 meses.

Conclusão: O melanoma anorretal continua desafiante. Todos os esforços devem ser feitos para o diagnóstico precoce, tornando assim possível realizar a excisão local com margens negativas. A AAPR ainda é uma opção factível para tumores avançados ou quando o esfínter anal está comprometido.

© 2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.

Este é um artigo Open Access sob a licença de [CC BY-NC-ND](https://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Anal malignant melanoma is a rare and aggressive disease with no specific clinical symptoms and a poor outcome. It is often diagnosed at an advanced stage, presenting with hematogenous metastasis. The anorectal region is the most common site for development of primary melanoma within the alimentary tract. The majority of the lesions arises from the dentate line of the anal canal and tends to spread submucosally.

Historically, anal melanoma was treated with abdominoperineal resection (APR), but recently some studies demonstrated no difference of the survival rates comparing to wide local excision (WLE). It appears that the only benefit of radical surgery is to obtain clear margins in tumor that are particularly bulky or invading the sphincter, and here APR should be considered. So, WLE offers the advantage of avoiding a permanent colostomy and is the preferred treatment when negative margins can be achieved.¹⁻⁴

Methods

The data of nine patients with anorectal melanoma were collected and retrospectively analyzed. From 1977 to 2006 we had a total of nine cases, including one male and eight females. Patients complaint, tumor characteristics, type of surgery, distant metastasis and overall survival were analyzed.

Due to the small number of patients, statistics analysis was not carried out.

Results

There were one male and eight females, of median age of 69 (41-85) years. Most frequent complaint was rectal bleeding. Two patients had amelanotic melanomas. Among nine patients, none presented with distant metastasis when the time of diagnostic. Six were Caucasian.

Seven patients underwent WLE, and one patient whose biopsy revealed melanoma refused any further treatment. This patient returned two years later with a bulky bleeding tumor, and a palliative sigmoidostomy was performed combined with embolization due to severe bleeding. One patient, at the time of diagnosis, presented as frozen pelvis, and had not enough time to a surgical approach. The median overall survival was 24 months. Among patients who underwent WLE we missed the follow up of one patient, one patient presented

a stroke and died five years after the procedure, and one patient is still alive (Figs. 1-6) (Table 1).




Fig. 1 – In clock hour: Nodular lesion with yellow pigmentation at the top (arrow). Dark pigmentation on the basis of the nodular tumoration. Intense cellular pleomorphism and melanotic pigment in the cytoplasm (case one).




Fig. 2 – In clock hour: Dark pigmentation arising in anal verge extending to polypoid lesion in distal rectum (arrows). Wide local excision performed preserving the esfínter muscle. Melanotic pigment in the cytoplasm of neoplastic cells (case two).




Fig. 3 – In clock hour: Typical dark nodular lesion in anal margin with black pigmentation (arrows). Histopathologic findings suitable of malignant melanoma (case four).




Fig. 5 – In clock hour: Fungiform dark mass in distal rectum. After neoadjuvant radiotherapy, wide local excision with loop ileostomy. Brain methastasis one month after surgery. Histopathologic findings show the lesion at anal canal and extending to distal rectum (case seven).




Fig. 4 – In clock hour: Vegetant and invasive lesion emerging from anal margin to pelvis, compromising rectal wall. Due to massive bleeding, it was performed arterial occlusion with coil (arrows). Late view after palliative radiotherapy (case six).




Fig. 6 – In clock hour: Nodular lesion with dark pigmentation at the basis in anal verge (arrows). Local excision with sphincter preservation and marsupialization of the surgical incision. Complete healing at 180 days (case eight).

Discussion

Anorectal malignant melanoma is a rare mucosal disease with a particularly aggressive biology compared with cutaneous melanoma of equal stage, accounting for approximately 1-4% of anorectal malignancies,^{2,5} but it is the third most common site after skin and eye and represents 0.6-1.6% of all melanomas.^{6,7}

The majority of patients are Caucasian, with the highest incidence during sixth and seventh decade. There is a slight female preponderance. The anorectal melanoma arises from melanocytes present in the transitional zone of the surgical anal canal and tends to spread submucosally.^{8,9} Related to its no specific symptoms, most of them, presenting with bleeding, prolapsed mass and anorectal pain, almost 60% of patients have already disseminated disease at initial diagnosis. Melano-

mas are commonly mistaken for hemorrhoidal disease, and the final diagnosis can be confirmed by positive excisional biopsy.^{1,2} The lesion is not pigmented in about 30% of cases and may resemble a villous carcinoma, and carries a worse prognosis by its invasive nature.^{2,7,9}

Immunohistochemical studies should always be done for establishing the diagnosis of melanoma. It is mostly positive for protein S-100 with a reported rate of 100%, melanoma antigen HMB-45 and vimentin.^{8,10} Others tests, as endoluminal ultrasound and computed tomography, should be performed to address the extension and presence of metastatic disease as its

Table 1 – Cases of anal melanoma.

CASES	Year	Age	Gender	Local	Complaint	Tumor appearance	Surgery	Adjuvant therapy	Metastasis or recurrence (months)	Survival
1	1977	71	Female	Anal	Bleeding	Hemorrhoidal thrombosis	Local excision	Imuno + QT	Liver (24m)	70m
2	1977	69	Male	Anorectal	Bleeding	Anal pigmented nodule	Local excision	QT	Rectum (6m)	14m
3	1993	58	Female	Anorectal	Anal discharge	Rectal ulcerated mass	Local excision	QT + interferon	Lung (18m)	23m
4	1995	85	Female	Anal	Bleeding	Anal pigmented nodule	Local excision	No	Groin (2m)	29m
5	1996	71	Female	Anorectal	Bleeding	Rectal polyp	Local excision	No	Rectum lymphnode (8m)	12m
6	1996	42	Female	Anorectal	Bleeding	Anal polyp	Sigmoidostomy + embolization	No	Liver (35m)	40m
7	2004	41	Female	Anorectal	Bleeding	Rectal pigmented nodule	Local excision + ileostomy	RT	Brain (1m)	8m
8	2006	81	Female	Anal	Nodule	Anal pigmented nodule	Local excision	No	No	alive
9	2006	58	Female	Anorectal	Bleeding	Rectal pigmented nodule and ulcerated mass	No	No	Frozen pelvis	1m

diagnosis. The computed tomography can reveals intraluminal masses in the distal rectum, with perirectal infiltration and often enlarged lymph nodes. Endorectal ultrasound is helpful in the evaluation of the tumor thickness and its nodal status.^{2,8}

Various factors, including duration of symptoms, inguinal lymph node involvement, tumor stage, the presence of amelanotic melanoma on histology, tumor necrosis, perineural invasion and tumor thickness, have been suggested to be negative prognostic factors. However, female sex has been suggested to be a positive prognostic factor for patients with cutaneous melanoma, and with an improved survival after radical resection for regional stage of anal melanoma. This reason is unclear.^{8,9,11}

The optimal treatment remains controversial, and surgery is based on two operative options: wide local excision (WLE) and abdominoperineal resection (APR). In the past, APR was advocated for the nonmetastatic disease, but as the prognosis was poor regardless of surgical approach, the goal of the surgical procedure should be based on obtaining negative margins and maintaining sphincter function. Most studies shows APR to provide a better local control, but no clear improvement in survival, and further consideration must be given to quality of life issues when making decisions between these two options.^{2,5,8,9,12,13,15}

Tumor thickness is a strong predictor factor for the risk of local recurrence and is used to plan therapeutic procedures. Tumor thickness below 1mm can be performed by local sphincter-saving excision with a 1cm safety margin. Tumor thickness between 1-4 cm should be excised by sphincter-saving excision and 2 cm safety margin, and tumor with thickness above 4 cm or with the involvement of sphincter should be treated with APR.^{8,9,11,13,14,18}

Stoidis et al. hypothesized that systemic dissemination is an early event in tumorigenesis, and by the time the lesion is clinically apparent micrometastases are well established. Metastases occur via lymphatic and hematogenous routes. Lymphatic spread to mesenteric nodes is more common than to inguinal nodes, while lungs, liver and bones are the most frequent sites of distant metastases.⁸

Prophylactic lymph node resection has no value, and the therapeutic lymph node resection should be performed only in the presence of positive inguinal nodes. Sentinel lymph node mapping (SLNM) has influenced the extension of surgical resection and seems to be helpful in preventing understating patients, who are pathologically node-positive but clinically node-negative and can allow early beneficial completion lymphadenectomy.⁵

The role of adjuvant therapy remains unknown. The response of anorectal melanoma to radio and/or chemotherapy continues to be poor. No systemic therapy regimen for metastatic anal melanoma is considered standard of care. Treatment is based on drugs developed for advanced cutaneous melanoma, although the clinical, biologic, and molecular seems to be different.⁸ Kim et al. used a combination of temozolomide, cisplatin and liposomal doxorubicin for metastatic anal melanoma with encouraging results.^{4,17}

Regardless of surgical approach, melanoma remains a highly lethal malignancy with overall 5-years survival rate less than 20%. The median survival is 34 months for patients with local disease and 10 months for those with metastatic disease.^{8,9}

The early diagnosis is the key to improved survival rate for patients with anal melanoma, due to the fact that the stage of the disease is the most important determinant in anorectal melanoma. A standard approach has not been established because of the limited number of patients of all anal melanoma reports. Further studies of the molecular mechanisms and tumor progression are needed to develop new treatment paradigms and improve survival.

Conclusion

Considering that anal melanoma is an aggressive tumor often diagnosed in advanced stages, a wide local excision should be considered as a therapeutic approach, despite controversial.

There's no significant impact in general survival with APR. So, WLE has its benefits in quality of life.^{13,16}

Conflicts of interest

The authors declare no conflicts of interest.

REFERENCES

- Zhou HT, Zhou ZX, Zhang HZ, Bi JJ, Zhao P. Wide local excision could be considered as the initial treatment of primary anorectal malignant melanoma. *Chin Med J (Engl)*. 2010 Mar;123(5):585-8.
- Trzcinski R, Kujawski R, Mik M, Sygut A, Dziki L, Dziki A. Malignant melanoma of the anorectum—a rare entity. *Langenbecks Arch Surg*. 2010 Jan 12.
- Khaled A, Hammami H, Faza B, Kourda N, Kamoun MR, Ben Jilany S, Zoghlami A. Primary amelanotic anorectal melanoma: an uncommon neoplasia with poor prognosis. *Pathologica*. 2009 Jun;101(3):126-9.
- Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. *Cancer* 2004, 100:1478-1483.
- Iddings DM, Fleisig AJ, Chen SL, Faries MB, Morton DL. Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? *Ann Surg Oncol* 2010;17:40-44.
- Nivatvongs S. Perianal and anal canal neoplasms. In: Gordon PH, Nivatvongs S, eds. *Colon, Rectum and Anus*. 3rd ed. New York: Informa Healthcare; 2007:369-390.
- Garrett K, Kalady MF. Anal neoplasms. *Surg Clin North Am* 2010;90:147-161, Table of Contents.
- Stoidis CN, Spyropoulos BG, Misiakos EP, Fountzilas CK, Paraskeva PP, Fotiadis CI. Diffuse anorectal melanoma: review of the current diagnostic and treatment aspects based on a case report. *World J Surg Oncol*. 2009 Aug 11;7:64.
- Sayari S, Moussi A, Bel Haj Salah R, Gherib SB, Haouet K, Zaouche A. Primary anorectal melanoma: a case report. *Tunis Med*. 2010 Jun;88(6):430-2.
- Seya T, Tanaka N, Shinji S, Shinji E, Yokoi K, Horiba K, et al. 2007. A case of rectal malignant melanoma showing immunohistochemical variability in a tumor. *J Nippon Med Sch* 74:377-381.
- Kiran RP, Rottoli M, Pokala N, Fazio VW. Long-term outcomes after local excision and radical surgery for anal melanoma: data from a population database. *Dis Colon Rectum*. 2010 Apr;53(4):402-8.
- Bullard KM, Tuttle TM, Rothenberger DA, et al. Surgical therapy for anorectal melanoma. *Journal of the American College of Surgeons* 2003;196:206-211.
- Thibault C, Sagar P, Nivatvongs S, Ilstrup DM, Wolff BG. Anorectal melanoma — an incurable disease? *Dis Colon Rectum* 1997;40:661-668.
- Weyandt GH, Eggert AO, Houf M, Raulf F, Brocker EB, Becker JC. Anorectal melanoma: surgical management guidelines according to tumour thickness. *Br J Cancer* 2003;89:2019-2022.
- Yeh JJ, Shia J, Hwu WJ, et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. *Ann Surg* 2006;244:1012-1017.
- Martínez-Hernández-Magro P, Villanueva-Sáenz E, Chávez-Colunga L. Anal malignant melanoma. Case report and literature review. *Rev Gastroenterol Mex*. 2009 Jan-Mar;74(1):39-44.
- Hay A, Liong J, Kumar D, Glees J. A striking response of anorectal melanoma to radiotherapy (locoregional disease confined to perineum and anal canal). *Ann R Coll Surg Engl*. 2010 Jan;92(1):W10-2.
- Nilsson PJ, Ragnarsson-Olding BK. Importance of clear resection margins in anorectal malignant melanoma. *Br J Surg*. 2010 Jan;97(1):98-103.